IDEAS home Printed from https://ideas.repec.org/p/col/000091/004328.html
   My bibliography  Save this paper

Mercado de Medicamentos, Regulación y Políticas Públicas

Author

Listed:
  • Hernán Jaramillo Salazar
  • José Manuel Restrepo Abondano
  • Catalina Latorre Santos

Abstract

Este documento tiene el propósito de analizar el documento de Fedesarrollo: "Efectos económicos y sociales de la regulación sobre la industria farmacéutica colombiana: El caso de los estudios de bioequivalencia y biodisponibilidad de los secretos empresariales y las buenas prácticas de manufactura" Zuleta and Junca (2001), tanto en sus aspectos conceptuales y metodológicos, como de resultados. El estudio se centra en tres aspectos esenciales: la exigencia de estudios de biodisponibilidad y bioequivalencia (ByB) relacionados con la obtención-renovación de registros sanitarios por parte de la industria farmacéutica; el secreto empresarial relacionado con la calificación de la información que sustenta los registros, y la aplicación de las medidas relacionadas con las buenas prácticas de manufactura (BPM).

Suggested Citation

  • Hernán Jaramillo Salazar & José Manuel Restrepo Abondano & Catalina Latorre Santos, 2003. "Mercado de Medicamentos, Regulación y Políticas Públicas," Borradores de Investigación 4328, Universidad del Rosario.
    • Handle: RePEc:col:000091:004328
    as

    Download full text from publisher

    File URL: http://repository.urosario.edu.co/bitstream/handle/10336/11281/4328.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Miller, Richard D. & Frech, Ted, 2002. "The Productivity of Health Care and Pharmaceuticals: Quality of Life, Cause," University of California at Santa Barbara, Economics Working Paper Series qt4b55f1xp, Department of Economics, UC Santa Barbara.
    2. Frank R. Lichtenberg, 2007. "Benefits and costs of newer drugs: an update," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 485-490.
    3. Arora, Ashish, 1996. "Contracting for tacit knowledge: the provision of technical services in technology licensing contracts," Journal of Development Economics, Elsevier, vol. 50(2), pages 233-256, August.
    4. Lanjouw, Jean O. & Cockburn, Iain M., 2001. "New Pills for Poor People? Empirical Evidence after GATT," World Development, Elsevier, vol. 29(2), pages 265-289, February.
    5. Mattias Ganslandt & Keith E. Maskus & Eina V. Wong, 2001. "Developing and Distributing Essential Medicines to Poor Countries: The DEFEND Proposal," The World Economy, Wiley Blackwell, vol. 24(6), pages 779-795, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Johanna Vásquez Velásquez & José Vicente Cadavid Herrera & Andrés Ramírez Hassan & Karoll Gómez Portilla, 2013. "Elasticidad de la demanda por medicamentos en el mercado farmacéutico privado en Colombia," Revista Ecos de Economía, Universidad EAFIT, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ramesh Govindaraj & Gnanaraj Chellaraj, 2002. "The Indian Pharmaceutical Sector : Issues and Options for Health Sector Reform," World Bank Publications - Books, The World Bank Group, number 15231, December.
    2. Panle Jia & Pinelopi K. Goldberg & Shubham Chaudhuri, 2006. "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India," American Economic Review, American Economic Association, vol. 96(5), pages 1477-1514, December.
    3. Padmashree Gehl Sampath, 2010. "Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry," Working Papers id:3336, eSocialSciences.
    4. Alexandre Almeida & Aurora A.C. Teixeira, 2008. "One size does not fit all… An economic development perspective on the asymmetric impact of Patents on R&D," FEP Working Papers 292, Universidade do Porto, Faculdade de Economia do Porto.
    5. Arora, Ashish & Fosfuri, Andrea, 1999. "Exploring the internalization rationale for international investment: wholly owned subsidiary versus technology licensing in the worldwide chemical industry," DEE - Working Papers. Business Economics. WB 6430, Universidad Carlos III de Madrid. Departamento de Economía de la Empresa.
    6. Iain M. Cockburn & Megan J. MacGarvie, 2011. "Entry and Patenting in the Software Industry," Management Science, INFORMS, vol. 57(5), pages 915-933, May.
    7. Matthias Krakel, 2005. "On the Benefits of Withholding Knowledge in Organizations," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 12(2), pages 193-209.
    8. Pedro Mendi, 2005. "The Structure of Payments in Technology Transfer Contracts: Evidence from Spain," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 14(2), pages 403-429, June.
    9. Pedro Mendi & Rafael Moner-Colonques & José J. Sempere-Monerris, 2016. "Optimal know-how transfers in licensing contracts," Journal of Economics, Springer, vol. 118(2), pages 121-139, June.
    10. Ming Liu & Sumner LaCroix, 2011. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 201116, University of Hawaii at Manoa, Department of Economics.
    11. Bate, Roger & Jin, Ginger Zhe & Mathur, Aparna, 2011. "Does price reveal poor-quality drugs? Evidence from 17 countries," Journal of Health Economics, Elsevier, vol. 30(6), pages 1150-1163.
    12. Rafael Moner-Colonques & Jose J. Semperes-Monerris, 2012. "Liscensing Policies in North-South Technology Transfers," NCID Working Papers 12/2012, Navarra Center for International Development, University of Navarra.
    13. Parida Wubulihasimu & Werner Brouwer & Pieter van Baal, 2016. "The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 1005-1019, August.
    14. Lanjouw, J.O., 1997. "The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?," Papers 775, Yale - Economic Growth Center.
    15. Ryan, Michael P., 2010. "Patent Incentives, Technology Markets, and Public-Private Bio-Medical Innovation Networks in Brazil," World Development, Elsevier, vol. 38(8), pages 1082-1093, August.
    16. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    17. repec:wip:wpaper:3 is not listed on IDEAS
    18. Apostolos Tsiachristas† & Ren頇oudriaan & Wim Groot, 2013. "The welfare effects of innovative pharmaceuticals: an international perspective from the Dutch experience," Applied Economics, Taylor & Francis Journals, vol. 45(9), pages 1219-1226, March.
    19. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016. "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
    20. Gambardella, Alfonso & Giuri, Paola & Luzzi, Alessandra, 2007. "The market for patents in Europe," Research Policy, Elsevier, vol. 36(8), pages 1163-1183, October.
    21. Cebrián, M. Mar, 2000. "Contratos de transferencia de tecnología y crecimiento de la economía española: 1959-1972," IFCS - Working Papers in Economic History.WH dh000301, Universidad Carlos III de Madrid. Instituto Figuerola.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:col:000091:004328. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Facultad de Economía (email available below). General contact details of provider: https://edirc.repec.org/data/ferosco.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.